Bioequivalence Study of Two Dabigatran Etexilate Mesylate Capsules in Healthy Subjects

Inclusion Criteria: * Healthy male or female subjects over 18 years old ( including 18 years old ) ; * Weight index in the range of 19.0 \~ 26.0 kg / m2 ( including the critical value * male weight is not less than 50 kg, female weight is not less than 45 kg ; * Subjects fully understand the purpose, nature, method and possible adverse reactions of the test, volunteer as subjects, and sign informed consent. Exclusion Criteria: * The researchers determined that the clinical significance of the cardiovascular system, respiratory system, digestive system, urinary system, endocrine system ; * Subjects with clinically significant abnormalities in physical examination, vital signs, laboratory tests ( creatinine clearance \< 80 mL / min ), 12-lead electrocardiogram ( ECG ), or chest X-ray ( posteroanterior and lateral views ) as deemed by the investigator ; * Positive results for any of the hepatitis B surface antigen ( HBsAg ), hepatitis B e antigen ( HBeAg ), hepatitis C virus ( HCV ) antibody, human immunodeficiency virus ( HIV ) antibody, or treponema pallidum antibody (TP-Ab) ; * The investigators determined a history of clinically significant food, drug allergies or other allergic diseases ( asthma, urticaria, eczema dermatitis, etc. ) or any excipients or similar drugs in dabigatran etexilate mesylate capsules have a history of allergy ; * Subjects with coagulopathy, bleeding tendency ( e.g., recurrent gingival bleeding ), history of bleeding events associated with incr…